Abstract Aim In the Apixaban for Reduction in Stroke and Other Thromboembolic Events in
Atrial Fibrillation (ARISTOTLE) trial, apixaban compared with warfarin reduced the risk of …

Objective We describe the incidence, location and management of non-major bleeding, and
assess the association between non-major bleeding and clinical outcomes in patients with …

Objectives: This study sought to characterize major bleeding on the basis of the components
of the major bleeding definition, to explore major bleeding by location, to define 30-day …

Summary Background The Apixaban for Reduction in Stroke and Other Thromboembolic
Events in Atrial Fibrillation (ARISTOTLE) trial showed that apixaban is better than warfarin at …

Aims It is uncertain whether the benefit from apixaban varies by type and duration of atrial
fibrillation (AF). Methods and results A total of 18 201 patients with AF [2786 (15.3%) with …

Aims The risk of stroke in patients with atrial fibrillation (AF) increases with age. In the
ARISTOTLE trial, apixaban when compared with warfarin reduced the rate of stroke, death …

Background Vitamin K antagonists are highly effective in preventing stroke in patients with
atrial fibrillation but have several limitations. Apixaban is a novel oral direct factor Xa …

Aim To assess clinical outcomes, efficacy, and safety according to sex during
anticoagulation with apixaban compared with warfarin in patients with atrial fibrillation …

Background Apixaban was shown to be superior to adjusted-dose warfarin in preventing
stroke or systemic embolism in patients with atrial fibrillation (AF) and at least one additional …

Background Recent reports suggest an important contribution from frequent off-label use of
apixaban 2.5 mg twice daily to the higher rates of thromboembolic events observed in …